InflaRx NV
Gesloten
1.76 1.15
Overzicht
Wijziging aandelenprijs
24u
Min
1.72
Max
1.81
Inkomsten | 3.2M -5.7M |
|---|---|
EPS | -0.08 |
Winstmarge | 16,200.567 |
Werknemers | 65 |
EBITDA | 8.5M -5.5M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +366.86% upside |
Marktkapitalisatie | 104M 258M |
|---|---|
Vorige openingsprijs | 0.61 |
Vorige sluitingsprijs | 1.76 |
InflaRx NV Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
InflaRx NV Prognose
Koersdoel
By TipRanks
366.86% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 8.17 USD 366.86%
Hoogste 14 USD
Laagste 4 USD
Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor InflaRx NV - Dist. in de afgelopen 3 maanden.
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over InflaRx NV
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
